$同源康医药-B(0_老虎社区_美港股上老虎

$同源康医药-B(02410)$ TY-9591具备成为“best-in-class”的潜力，若拓展至一线治疗适应症，市场规模或突破50亿元，叠加海外授权，公司有望跻身创新药第一梯队

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":519525293494312,"tweetId":"519525293494312","gmtCreate":1767858565818,"gmtModify":1767858568173,"author":{"id":4218427800237090,"idStr":"4218427800237090","authorId":4218427800237090,"authorIdStr":"4218427800237090","name":"莎士比亚的微笑","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> TY-9591具备成为“best-in-class”的潜力，若拓展至一线治疗适应症，市场规模或突破50亿元，叠加海外授权，公司有望跻身创新药第一梯队</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> TY-9591具备成为“best-in-class”的潜力，若拓展至一线治疗适应症，市场规模或突破50亿元，叠加海外授权，公司有望跻身创新药第一梯队</p></body></html>","text":"$同源康医药-B(02410)$ TY-9591具备成为“best-in-class”的潜力，若拓展至一线治疗适应症，市场规模或突破50亿元，叠加海外授权，公司有望跻身创新药第一梯队","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/519525293494312","repostId":0,"isVote":1,"tweetType":1,"viewCount":197,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02410"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":141,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}